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Current data suggest that apoptosis controls neutro-
phil numbers in tissues. We analyzed roles for and the
sites of action for the cAMP-dependent protein kinases
(cAPKs) in apoptosis induced in human neutrophils by
in vitro storage, cycloheximide (CHX) exposure, and an-
ti-Fas exposure. Treatment with 8-chlorophenylthio-
cAMP (8-CPT-cAMP) prolonged the time required for
50% of the cells to exhibit apoptotic morphology (t50)
from 16.3 to 41.8 h (in vitro culture), from 2.4 to 7.8 h
(CHX), and from 4.8 to 6.5 h (anti-Fas). CHX 6 8-CPT-
cAMP did not significantly alter resting intracellular
calcium levels and H-89, a selective inhibitor of cAPK,
had no effect on apoptosis in the absence of the ana-
logue. In contrast, site-selective cAMP analogues that
specifically activated the type I cAPK, but not type II
cAPK, synergistically attenuated apoptosis. Exposure to
8-CPT-cAMP delayed, in parallel, the activity of
caspase-3 (CPP-32b), whereas mitogen-activated protein
kinase kinase (MAPKK) inhibitor, PD98059, had no ef-
fect on CHX-induced apoptosis 6 8-CPT-cAMP. Together
these results indicate that type I cAPK activation is
necessary and sufficient to mediate cAMP-induced de-
lay in human neutrophil apoptosis induced by several
mechanisms and suggest that one of the major sites of
cAPK action is upstream of caspase-3 (CPP-32b)
activation.
Human neutrophils are short-lived cells that play important
roles in both host defense and acute inflammation in humans
(1, 2). Recent data suggest that apoptosis, a physiologic mech-
anism for cell death, regulates both production and survival of
neutrophils, representing a basic biological mechanism for this
cell type (3–6). Various inflammatory mediators are known to
accelerate or delay apoptosis in neutrophils (7–9), but little
about the intracellular signaling pathways that regulate this
process (10) is understood. Recent evidence indicates that a
family of cysteine proteases, the caspases, are critical compo-
nents of apoptosis cascades, are primary determinants for the
orderly disassembly of structural components, and incapacitate
repair and homeostatic mechanisms in cells (10). Roles for
caspase proteases in apoptosis have been analyzed in several
cell types but have not been investigated in neutrophils.
Intracellular signaling mechanisms typically involve protein
kinases as major regulators of cellular processes (11). The
cAMP-dependent protein kinases (cAPK),1 one of the best un-
derstood classes of protein kinases, are tetramers composed of
two regulatory (R) and two catalytic (C) subunits and are
functionally regulated by cAMP (12–14). Binding of cAMP to
the R subunit releases the catalytically active C subunit from
the R subunit, resulting in protein phosphorylations. This ac-
tivates downstream signaling and transcription events, which
likely account for recognized roles for cAMP in neutrophil che-
motaxis (15), neutrophil respiratory burst activity (16), and
more recently, apoptosis in neutrophils and other cell types
(17–20). The cAPK exists as two major isoforms, type I and type
II, with different R subunits, RI and RII subunits, respectively
(12–14). The R subunits exhibit two different cAMP binding
sites, designated sites A (or site 2) and B (or site 1), which
interact with positive cooperativity for binding cyclic nucleo-
tides, activating the C subunit and regulating physiological
responses (14, 21). This positive cooperativity provides a phys-
iological amplification mechanism for cAMP-mediated events
that occur through cAPK and a means for distinguishing be-
tween activation of type I and type II cAPK by using cAMP
analogues that bind differently to sites A and B on type I and
type II cAPK.
In the following studies, we utilized three different models
for apoptosis, i.e. in vitro storage, cycloheximide exposure, and
anti-Fas exposure, to examine the roles for cAMP and cAPK
and potential sites of action in this process. Apoptosis was
quantified using morphologic changes and annexin V-FITC
binding as markers. cAPK activity was manipulated by cAMP
analogue exposure, inhibition using selective inhibitors, and
synergistic activation with type-specific cAMP analogue pairs.
Caspase substrates (22, 23) and inhibitors of MAPKK (24) were
utilized to define sites of convergence between cAPK and
apoptosis pathways. The data show that stimulation of cAPK
activity delays apoptosis in all three model systems and that
activation of type I cAPK is responsible for the observed effects
by delaying the activation of the cysteine protease, caspase-3.
MATERIALS AND METHODS
Isolation of Neutrophils—Heparinized (;1 unit/ml) venous blood was
obtained from healthy adult volunteers of either sex. Neutrophils were
purified by sedimentation through a Hypaque-Ficoll step gradient, dex-
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tran sedimentation, and hypotonic lysis as described previously (25).
The resulting preparations were .95% neutrophils by morphology and
greater than 98% viable (trypan blue exclusion).
For some experiments, purified neutrophils were resuspended in
50% autologous plasma that was harvested from above the Hypaque-
Ficoll gradient after the initial purification step. This plasma was
sedimented (500 3 g, 10 min, 4 °C) to remove cellular elements and
passed through a 0.45-mm filter to remove contaminating platelets
before use.
Apoptosis Models—Three different methods for apoptosis induction
were employed. For in vitro storage of neutrophils, 1 ml aliquots of 5 3
106 freshly purified cells (RPMI 1640 medium, 10% fetal bovine serum)
were placed in 1.5 ml unsealed polypropylene microcentrifuge tubes
and held at 37 °C, 5% humidified CO2 for 0, 2, 4, 6, 8, 24, and 48 h. For
cycloheximide exposure of neutrophils, 1 ml aliquots (5 3 106 cells in
either RPMI 1640 medium, 10% fetal bovine serum, or 50% autologous
plasma) were supplemented with 1 mM cycloheximide (CHX) and stored
in unsealed 1.5-ml polypropylene microcentrifuge tubes at 37 °C, 5%
humidified CO2 for 0, 2, 4, 6, and 8 h. CHX-exposed cells in autologous
plasma were used in initial studies of cAMP effects and in cAMP
analogue synergism studies. CHX-exposed cells in RPMI 1640, 10%
fetal bovine serum were used in experiments to estimate t50 values. A
high concentration of CHX (1 mM) was used to shorten the time for
maximal apoptosis to 6–8 h. No necrosis was observed as determined
by trypan blue staining. For anti-Fas exposure of neutrophils, 1-ml
aliquots containing 5 3 106 cells in RPMI 1640, 10% fetal bovine serum
were supplemented with 100 or 500 ng/ml murine monoclonal IgM
anti-Fas (26) (CH-11, MBL, Nagoya, Japan) and stored at 37 °C, 5%
humidified CO2 for 0, 2, 4, 6 and 8 h.
Assessment of Apoptosis—Two methods were used for quantitative
assessment of neutrophil apoptosis. Morphologic apoptosis was esti-
mated as follows. 50-ml aliquots of cells from each apoptosis model were
diluted 1:3 with Hanks’ balanced salt solution with Ca21 and Mg21
(HBSSw), and 75 ml of cell suspension was applied to a glass slide using
a Cytospin III (Shandon Southern; Sewickley, PA). After air drying,
applied cells were stained with modified Wright-Giemsa stain (Diff-
Quik; Baxter Scientific, Miami, FL), dried, and examined microscopi-
cally. A minimum of 200 cells/slide were examined and graded as
apoptotic/non-apoptotic. In human neutrophils, morphologic changes of
apoptosis are striking (Fig. 1) and include separation of nuclear lobes,
replacement of heterogeneous nuclear chromatin staining with dense
homogeneous nuclear chromatin staining, loss of nuclear chromatin,
cellular and nuclear fragmentation, and basophilic cytoplasmic stain-
ing. For these studies, the morphologic criteria for neutrophil apoptosis
were 1) one or more densely stained nuclear fragments/cell, 2) absence
of chromatin within nuclear fragments, and/or 3) a cellular fragment
containing a densely stained nuclear fragment.
Annexin V-FITC binding was used as the second quantitative apo-
ptosis marker. Annexin V exhibits calcium-dependent binding to phos-
phatidylserine (27). Although phosphatidylserine is typically restricted
to the inner leaflet of the cell membrane in normal cells and is therefore
inaccessible to annexin V in solution, apoptotic cells express phosphati-
dylserine in their outer membrane leaflet (27), resulting in ready bind-
ing of annexin V to their surfaces. Annexin V-FITC labeling was per-
formed as recommended by the manufacturer (Alexis Corp.; San Diego,
CA). Neutrophils (5 3 105) from each experimental condition were
sedimented, resuspended in 100 ml of binding buffer (10 mM HEPES/
NaOH, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4) containing 1 mg/ml
annexin V-FITC and held at room temperature for 10 min in the dark.
Labeled cells were washed once in the same buffer, and a wet prepa-
ration of cells was examined with an Olympus BH-2 epifluorescence
photomicroscope. After minimizing background phase-contrast illumi-
nation to allow identification of all cells in a field, epifluorescence
illumination was added, and a minimum of 350 cells were examined on
each slide and graded as annexin V positive (bright green-yellow fluo-
rescence) or negative (weak or no fluorescence).
Chromatin fragmentation was examined as a qualitative marker for
apoptosis in CHX-exposed neutrophils only (28). Aliquots (2.5 3 106) of
neutrophils from different conditions were resuspended in 400 ml of
lysis buffer (0.2% Triton X-100, 10 mM Tris, 1 mM EDTA) and after
vigorous mixing, were allowed to sit on ice for 20 min. After the addition
of 5 M NaCl (100 ml) and isopropanol (500 ml), samples were held at
220 °C for 60 min and sedimented at 14,000 rpm for 10 min, and the
pellet was retrieved and dried. After resuspension of the pellet in 20 ml
of TBE (90 mM Tris-borate, 25 mM disodium EDTA, pH 8.3), 4 ml of 30%
Ficoll were added, and the sample was boiled for 5 min. Electrophoresis
was carried out in a 1.5% agarose gel at 30 V for 18–20 h. After
electrophoresis, the agarose gel was stained with ethidium bromide and
photographed under ultraviolet illumination.
T50 Determinations—The time required for 50% of neutrophils to
undergo morphologic apoptosis (t50) was determined by plotting the
percentage of apoptotic forms observed at each time point and defining
the time at which 50% of the cells exhibited apoptotic forms by linear
regression of data points as indicated in the legend to Fig. 2. The t50
value for in vitro storage was determined by linear regression between
the 24 and 48 h time point and represents an estimation. Unless
otherwise noted, all t50 determinations are based on the observation of
cells suspended in RPMI 1640 medium, 10% fetal bovine serum, with
appropriate additions.
Cyclic AMP Analogue and PD98059 Exposures—To examine the
effects of cAMP on apoptosis induction, exposure to 8-CPT-cAMP, a
membrane-permeant, relatively phosphodiesterase-resistant cAMP an-
alogue, was used alone at varying concentrations and for varying du-
rations. To determine if MAPKK was involved in the cAMP effect,
incubations were carried out in the presence or absence of 100 mM
PD98059 (Calbiochem), a mitogen-activated protein kinase kinase
(MAPKK)-specific inhibitor (24). Neutrophils were exposed to 8-CPT-
cAMP for 10 min before apoptotic stimuli were added, and remained
exposed to 8-CPT-cAMP throughout these experiments. When PD98059
was present, preincubation was for 1.5 h, and the inhibitor remained
throughout the experiment.
Cyclic AMP analogue synergism experiments utilized pairs of differ-
ent cAMP analogues to determine which cAPK isotype (14, 21, 29) was
responsible for effects on apoptosis induction. Cyclic AMP analogues
bind selectively to the two cAMP binding sites (site A and site B) on the
R subunit of cAPK and can mimic the positively cooperative binding of
cAMP that normally occurs at these sites and leads to activation of
cAPK (14, 21, 29, 30). This positive cooperativity of binding is reflected
in a positive cooperativity of cAPK activation and cAPK-mediated cel-
lular responses. Depending on their structures, cAMP analogues at low
concentrations selectively bind to either site A or site B. By using
specific pairs of cAMP analogues (one that binds to site A only and the
other that binds to site B only), it is possible to mimic the cooperative
binding of cAMP and initiate cAPK-specific cell responses that, in the
presence of both analogues, are greater than the sum of the responses
to the individual analogues alone. Low concentrations of analogues are
required to maintain the selectivity of binding at the respective sites.
High concentrations of a single analogue result in binding to both sites
A and B and the potential for cooperative binding to R and activation of
cAPK, and synergism of cell responses by two separate analogues are
lost. Furthermore, it is possible to use specific cAMP analogue pairs
that bind differently to sites A and B on the type I versus the type II
cAPK to differentiate responses that are mediated by each cAPK iso-
type. Consequently, specific pairs of analogues were used to determine
the involvement of cAPK type I or type II in cAMP-mediated effects.
Neutrophils stored in vitro, exposed to CHX, or exposed to anti-Fas
were combined with varying concentrations of appropriate site-selec-
tive/cAPK isotype-selective cAMP analogues as follows. The 8-CPT-
FIG. 1. Photomicrographs of freshly purified human neutro-
phils, demonstrating the morphologic changes of apoptosis. A,
freshly purified neutrophils show segmented nuclei with lobes attached
by chromatin threads, heterogeneous staining of nuclear chromatin,
and pale cytoplasm. B, cycloheximide-exposed (6 h) human neutrophils
exhibit separation or fragmentation of nuclear lobes, homogeneous
nuclear chromatin staining, loss of chromatin from nuclear fragments,
cellular fragmentation, shrinkage, and cytoplasmic basophilia. C, neu-
trophils exposed for 6 h to cycloheximide/8-CPT-cAMP (500 mM) show
occasional cells with apoptotic morphology.

















cAMP/8AHA-cAMP pair (8CPT/8AHA) and the N6B-cAMP/8AHA pair
(N6B/8AHA) were used as type I cAPK-specific pairs. The 8-CPT-cAMP/
N6B-cAMP pair (8CPT/N6B) and the 8-CPT-cAMP/N6MB-cAMP pair
(8CPT/N6MB) were used as type II cAPK-specific pairs as described
previously (14, 21, 29, 30). In all experiments, the priming analogue
concentration was adjusted to achieve 5–10% maximum effect, and the
concentration of the other analogue in the pair was varied. The effects
of the priming analogue A alone and the second analogue B alone were
arithmetically summed to estimate the predicted effect of the A 1 B
mixture. This predicted response was compared with the experimen-
tally observed response to the “A 1 B” mixture. If synergy was present,
the observed A 1 B response was greater than the predicted A 1 B
response. If no synergy was present, the observed A 1 B response and
the predicted A 1 B response were equal.
Measurements of the Intracellular Free Calcium Concentration—Pu-
rified neutrophils were adjusted to 5 3 106/ml in Hanks’ balanced salt
solution without Ca21 or Mg21 (HBSSw/o) and loaded with 2.5 mM
Fura2AM (Molecular Probes; Eugene, OR) for 45 min, 37 °C, 5% CO2 in
dark. After loading, cells were sedimented, washed twice in 15-ml
volumes of 4 °C HBSSw/o, readjusted to 107 cells/ml in 50% autologous
plasma 6 1 mM CHX, 6 500 mM 8-CPT-cAMP in aliquots, and incubated
at 37 °C, 5% CO2 in the dark for the times specified. After incubation,
cells were sedimented, resuspended in HBSSw at 6 3 106/ml, and
examined in an LS50B spectrofluorometer (Perkin-Elmer) with excita-
tion wavelengths of 340 and 380 nm and emission wavelength of 510
nm.
In the spectrofluorometer, the Fura2 fluorescence of each cell aliquot
was measured with cells alone, cells 1 0.1% Triton X-100, and cells 1
0.1% Triton X-100 1 20 mM EGTA to measure basal cell signal, maxi-
mum ratio of Fura2 fluorescence, and minimum ratio of Fura2 fluores-
cence, respectively. The recorded fluorescence levels were then used to
calculate the resting intracellular calcium concentration as described
(33). The fluorescence intensity of loaded cells was noted to decrease
progressively over the 210 min of incubation in 50% plasma (fresh, 67 6
4 fluorescence units, n 5 5; 210 min, 18 6 2 fluorescence units, n 5 5),
which precluded loading cells at time 0 and following intracellular
calcium levels over time. Therefore, cells were first incubated for 4 h
then loaded with Fura2AM and examined for their intracellular free
calcium levels.
cAPK Inhibition Experiments—The selective cAPK inhibitor H-89
(Sigma) was prepared as a 10 mM stock in water and used at final
concentrations of 5 and 25 mM.
Quantitation of Interleukin-1b-converting Enzyme (ICE)-specific and
CPP-32b-specific Activity—Neutrophils (5 3 106) were lysed in 100 ml of
10 mM potassium phosphate, 1 mM EDTA buffer containing 0.5% Triton
X-100 supplemented with 2 mM phenylmethylsulfonyl fluoride, 10
mg/ml leupeptin, 10 mg/ml pepstatin, 10 mM dithiothreitol for 15 min
and spun at 14,000 rpm for 20 min. The lysate (100 mg) was diluted to
1 ml with ICE buffer (50 mM HEPES, 10% sucrose, 0.1% Chaps, pH 7.5)
containing 50 mM YVAD-AFC (tyrosine-valine-alanine-aspartate-7-ami-
no-4-trifluoromethyl coumarin) or DEVD-AFC (aspartate-glutamate-
valine-aspartate-AFC) (22, 23) and 10 mM freshly prepared dithiothre-
itol. After various incubation times at 37 °C, 500 ml of reaction mixture
was diluted with 1.5 ml of ICE buffer and fluorescence (excitation 400
nm and emission 505 nm) was read at 1- and 2-h time points. The
release of the fluorochrome was linear with time and protein concen-
tration used. Blanks in the absence of cell lysates were also carried out
to determine background fluorescence. Standards containing 0–1500
nM AFC were utilized to determine the amount of fluorochrome re-
leased. Specificity for caspase-3 activity, as opposed to nonspecific hy-
drolysis of DEVD-AFC was demonstrated by the inhibitor DEVD-CHO
(DEVD aldehyde). Very low levels of nonspecific activity were present,
and the effects of the inhibitor were concentration-dependent.
Statistical Analysis—Results are reported as mean 6 S.E. values,
with the number of different experiments indicated as the value for n.
Summary means are compared by Student’s t test, and when natural
pairing occurs within an experiment, the paired sample t test is used.
Statistical significance is declared at p , 0.05.
RESULTS
The Effects of 8-CPT-cAMP on Apoptosis Induction in Three
Different Models Using Three Different Indicators of Apo-
ptosis—The results shown in Table I compare two quantitative
markers of apoptosis, morphology and annexin V-FITC bind-
ing, in three different models of apoptosis. In vitro culture,
CHX exposure, and anti-Fas exposure induced extensive apo-
ptosis in all three models, as indicated by both markers. At the
indicated time points, both markers demonstrated that 500 mM
8-CPT-cAMP inhibited apoptosis in all three models. Annexin
V-FITC was a more sensitive marker for the effects of cAMP
than morphology, especially for the CHX model. This might be
expected for an early marker of apoptosis such as annexin
V-FITC versus a later marker of apoptosis such as morphology
(31).
To demonstrate the temporal characteristics of apoptosis for
each model in the presence and absence of cAMP, Fig. 2 shows
time courses for apoptosis in the presence and absence of
8-CPT-cAMP in all three models using morphology as the
apoptosis marker. Table II indicates the time required for 50%
of the cells to exhibit apoptotic morphology (t50) as determined
from the time courses in Fig. 2. Compared with in vitro culture
alone, induction of apoptosis by CHX and anti-Fas binding in
the absence of cAMP analogue decreased the t50 values by 6.8-
and 3.4-fold, respectively. In the presence of 500 mM 8-CPT-
cAMP, apoptosis was delayed in all three models in a time-de-
pendent (Fig. 2, A–C) and a concentration-dependent (not
shown) manner. Cyclic AMP analogue treatment increased the
t50 values (Table II) 2.6-, 3.3-, and 1.4-fold for in vitro culture,
CHX-exposure, and anti-Fas-exposure, respectively. When
DNA fragmentation was used as a qualitative marker of apo-
ptosis, the intensity of DNA laddering in the presence of cAMP
analogue was less at all time points tested in the CHX model
(Fig. 3). Because of the qualitative nature of this indicator,
DNA fragmentation was not tested in the other models.
The time courses for apoptosis suggest that the cAMP-medi-
ated delay in apoptosis occurs in the initial phases of the
FIG. 2. Effects of time and 8-CPT-cAMP on morphologic apoptosis in human neutrophils stored in vitro (A), exposed to 1 mM
cycloheximide (B), and exposed to 500 ng/ml murine monoclonal anti-Fas (C). 8-CPT-cAMP (500 mM) was added to cells 10 min before the
initiation of in vitro culture, CHX, or anti-Fas exposure. The cAMP analogue remained throughout the experiment. Data shown are mean 6 S.E.
for 4–6 experiments.

















process (Fig. 2). In the presence of 8-CPT-cAMP, a decreased
rate of apoptosis is evident at early phases of the time course,
but later, the rates of apoptosis are similar in cAMP analogue-
treated and -untreated cells. It could be argued that this is due
to a decrease in the concentration of the analogue due to hy-
drolysis during the incubation. However, this seems unlikely
because 8-CPT-cAMP is relatively resistant to cAMP phos-
phodiesterases (32), and the same effect is observed in the in
vitro culture model, which is incubated for extended periods of
time.
In the CHX model, neutrophils were incubated in RPMI or
autologous plasma with or without 8-CPT-cAMP (Fig. 2B). In
the absence of cAMP analogue, apoptosis was greater in the
presence RPMI than in the presence of autologous plasma. The
presence or absence of autologous plasma had no effect on the
cAMP-mediated delay in apoptosis. Fas-induced apoptosis was
not observed in the presence of autologous plasma (not shown).
These results suggest that autologous plasma may contain
anti-apoptotic factors. No further studies were carried out to
define these putative factors.
Effects of Basal cAPK Inhibition on Spontaneous Neutrophil
Apoptosis—The inhibitory effects of cAMP analogue exposure
on morphologic apoptosis and annexin V-FITC binding in all
apoptosis models suggested a role for the cAPK using both
markers. To examine whether basal (unstimulated) cAPK ac-
tivity suppressed morphologic apoptosis in neutrophils, H-89, a
selective inhibitor of cAPK (33), was used. In the absence of
cAMP analogues, H-89 exposure had no significant effect on the
percentage of apoptotic forms after 8 h of in vitro cultivation
(control, 15.3% 6 2.3; 25 mM H-89, 9 6 1%), 6 h of CHX exposure
(control, 74.8 6 2.5; 25 mM H-89, 66 6 5.0%), or 6 h of anti-Fas
exposure (control, 73.7 6 5.4; 25 mM H-89, 70.1 6 9.9). These
results suggest that basal cAPK activity does not play a role in
suppressing neutrophil apoptosis.
The Effect of CHX Exposure on Intracellular Calcium Con-
centrations in the Presence and Absence of 8-CPT-cAMP—Be-
cause changes in intracellular free calcium concentrations are
reported to influence apoptosis in neutrophils (34), the effects
of CHX and 8-CPT-cAMP exposure on Fura2-based estimates
of intracellular calcium concentrations were examined. Intra-
cellular free calcium levels in control cells rose spontaneously
from 30 6 4 nM at 5 min to 65 6 12 nM at 210 min (n 5 5), and
these were not affected by 1 mM CHX exposure (27 6 2 nM and
81 6 22 nM respectively, n 5 5), 500 mM 8-CPT-cAMP exposure
(33 6 2 nM and 56 6 11 nM, respectively, n 5 5), or CHX 1
8-CPT-cAMP (29 6 2 nM and 62 6 12 nM, respectively, n 5 5).
Because no effect on intracellular free calcium concentration
was observed in the CHX apoptosis model, this approach was
not applied to the in vitro storage and anti-Fas exposure
models.
Determination of the cAPK Isoform Mediating the cAMP An-
alogue Effects—Exposure to cAMP analogues results in stimu-
lated rather than basal cAPK activity. Therefore, the lack of
effects from H-89 exposure did not eliminate a role for stimu-
lated cAPK in suppression of neutrophil apoptosis. To deter-
mine if cAPK activation played a role and to determine which
cAPK isotype was responsible for the observed cAMP analogue
effects, pairs of site-selective cAMP analogues specific for ei-
ther the type I or type II cAPKs were used in each model
system (see “Materials and Methods”).
A series of cAMP analogue concentration-response experi-
ments were first carried out to define analogue concentrations
that delayed relatively low levels of apoptosis, which is re-
quired by the method (21) and to determine the order of po-
tency of the analogues. As expected, all cAMP analogues tested
effectively delayed the expression of apoptosis using morphol-
ogy. The order of potency for the analogues was 8-CPT-cAMP .
N6B-cAMP 5 N6MB-cAMP . 8-AHA-cAMP.
Table III illustrates experiments for each of the three models
TABLE I
Two quantitative markers demonstrate that 8-CPT-cAMP inhibits
apoptosis induced by different stimuli
Isolated neutrophils were incubated in the presence or absence of
8-CPT-cAMP, and apoptosis was induced by in vitro culture, CHX
exposure, or anti-Fas exposure. At the indicated times, cells were ana-
lyzed for apoptotic morphology and annexin V-FITC binding as de-
scribed under “Materials and Methods.” The numbers represent the
mean and S.E. of the percentage of cells exhibiting the indicated mark-
ers from six experiments. Statistical significances of the effect of 8-CPT-
cAMP are indicated.
Conditions Morphology Annexin V-FITC
% of apoptosis % of apoptosis
In vitro culture (24 h) 75.5 6 6 81.4 6 4.2
In vitro culture 1 500 mM
8CPT-cAMP (24 h)
14.5 6 2a 17.6 6 5a
CHX, 1 mM (6 h) 93.9 6 1.7 94.3 6 1.7
CHX 1 500 mM 8CPT-cAMP
(6 h)
24 6 5.6a 42.3 6 1.7a
Anti-Fas 500 ng/ml (6 h) 60.5 6 4.4 71.2 6 2.8
Anti-Fas 1 500 mM 8CPT-
cAMP (6 h)
33.5 6 4.8b 45.6 6 5.3b
a p , 0.001.
b p , 0.01.
TABLE II
T50 values for the appearance of apoptotic morphology in the presence
and absence of 8-CPT-cAMP for three different apoptosis models
Apoptosis was induced by in vitro culture, CHX exposure (1 mM) and
anti-Fas exposure (500 ng/ml) in the presence and absence of 8-CPT-
cAMP (500 mM). At various times, cells were analyzed for apoptotic
morphology as described under “Materials and Methods.” The T50 val-
ues indicate the mean and S.E. (n 5 5) of the time required for 50% of
the cells to exhibit apoptotic morphology. The statistical significance of
the effect of 8-CPT-cAMP is indicated.
Conditions
T50 based on morphology
No addition 500 mM 8CPT-cAMP
In vitro culture 16.3 6 1.3 41.8 6 2.9a
CHX-1 mM 2.4 6 0.2 7.8 6 0.3a
Anti-Fas 500 ng/ml 4.8 6 0.5 6.5 6 0.3b
a p , 0.0001.
b p , 0.05.
FIG. 3. Chromatin fragmentation in human neutrophils ex-
posed to 1 mM cycloheximide. Agarose gel electrophoresis patterns
observed with molecular size markers (Mwt) (lane 1), neutrophils ex-
posed to 1 mM CHX for 2 h (lane 2), 4 h (lane 3), and 6 h (lane 4),
neutrophils exposed to 1 mM CHX 1 500 mM 8-CPT-cAMP for 2 h (lane
5), 4 h (lane 6), and 6 h (lane 7), control neutrophils at 6 h (lane 8), and
control neutrophils 1 500 mM 8-CPT-cAMP at 6 h (lane 9).

















of apoptosis that utilize pairs of site-selective cAMP analogues
that are specific for the cooperative activation of either type I or
type II cAPK. In all three models, the observed (A 1 B) effects
of the combination of all type I cAMP analogue pairs was
significantly greater than the predicted (A 1 B) effects. This
indicates that the combination of two type I, site-selective
analogues cooperatively activates the type I cAPK, which re-
sults in a synergistic delay of apoptosis. In contrast, for all type
II analogue pairs, the observed (A 1 B) effects of the combina-
tion of cAMP analogues was similar to the predicted (A 1 B)
effects. This indicates that cooperative activation of the type II
cAPK by the two type II site-selective analogues does not delay
apoptosis. In all three models of apoptosis induction and in all
experiments, synergism for the cAMP-induced delay of apopto-
sis was present when type I-specific cAMP analogues were used
but not when type II-specific cAMP analogues were used. These
data suggest that stimulation of the type I cAPK underlies
cAMP analogue-mediated suppression of apoptosis. This is con-
sistent with the finding that type I cAPK is the predominant
(80–85%) isoform in human peripheral neutrophils as deter-
mined by DEAE-Sepharose chromatography (data not shown).
Determination of the Site of cAPK in the Delay of Apopto-
sis—To determine the site(s) for cAPK-mediated delay in ap-
optosis, we examined whether activation of cAPK by 8-CPT-
cAMP in intact neutrophils affected caspase-3 (CPP-32b) or
caspase-1 (ICE) activity in vitro or affected apoptotic morphol-
ogy in the presence of MAPKK inhibition in intact neutrophils.
To determine if cAPK acted upstream or downstream of
caspase-3 (CPP-32b), we incubated the fluorochrome peptide
DEVD-AFC, a caspase-3 (CPP-32b)-specific substrate (22, 23),
with extracts from cells that were induced to undergo apoptosis
for various times with CHX (Fig. 4A) in the presence and
absence of 8-CPT-cAMP. Extracts from cells incubated for 2, 4,
or 6 h in the absence of CHX and 8-CPT-cAMP exhibited very
low levels of fluorescence, like that indicated at time 0 in Fig. 4.
In the presence of CHX alone, caspase-3 activity increased
between 0 and 4 h in a time-dependent manner and then
decreased between 4 and 6 h. This decrease in caspase activity
might be expected in a cell population when 80–100% of the
cells exhibit apoptotic morphology (see Fig. 2). In the presence
of 8-CPT-cAMP, there was a decrease in caspase-3 activity
compared with CHX exposure alone at the 2- and the 4-h time
point, and caspase-3 activity continued to increase. However,
after 6 h in the presence of cAMP analogue, caspase activity did
not reach the maximum seen in the absence of cAMP analogue.
Consequently, in the presence of 8-CPT-cAMP, the time course
for caspase-3 activity was shifted to the right. The delay in the
specific caspase activity was parallel to the delay in the appear-
ance of apoptotic morphology (Fig. 2) and annexin V-FITC
binding (not shown) when cAPK was activated in intact neu-
trophils in the CHX model. Results shown in Fig. 4B compare
the effects of 8-CPT-cAMP at single time points on caspase-
mediated proteolysis of DEVD-AFC in apoptosis induced by in
vitro culture, CHX-exposure, and anti-Fas exposure. In each
model, the activity of caspase-3 was decreased significantly in
the presence of the cAMP analogue. These results suggest that
cAPK delays apoptosis by acting at a site upstream of caspase-3
in all three models. This suggests that a site or sites is common
to all three mechanisms of apoptosis tested in these studies.
In experiments parallel to those shown in Fig. 4, extracts
from cells previously incubated in the presence and absence of
8-CPT-cAMP were incubated with a caspase-1 (ICE)-specific
fluorochrome substrate, YVAD-AFC (not shown). No caspase-1
(ICE) activity was observed in the presence or absence of cAMP
analogue. In agreement with the results of Martins et al. (23),
these experiments suggest that caspase-1 activity is not re-
quired for apoptosis and that cAPK has no effect on caspase-1
activity in any of the three models tested here.
To determine a potential role for MAPKK in apoptosis, iso-
lated human neutrophils were preincubated for 1.5 h with or
without 100 mM PD98059 (24) and exposed to CHX in the
presence or absence of 500 mM 8-CPT-cAMP (not shown). In the
absence or presence of CHX, PD98059 had no effect on neutro-
phil apoptotic morphology after 2, 4, or 6 h of incubation. As
shown in Fig. 2B, 8-CPT-cAMP significantly inhibited the ap-
pearance of apoptotic morphology, and this was not altered by
TABLE III
Site-selective cAMP analogue pairs specific for type I,
but not type II, demonstrate synergism for delay
in apoptosis induced by in vitro culture
Isolated human neutrophils were maintained in culture for 24 h (A),
incubated in the presence of 1 mM CHX for 6 h (B), incubated in the
presence of anti-Fas (500 ng/ml) for 4 h (C), in the presence and absence
of various site-selective cAMP analogues alone (A or B) or in pairs (A 1
B) at the indicated concentrations as described under “Material and
Methods.” Pairs of cAMP analogues that are specific for type I are
8-CPT-cAMP (site A-selective) and 8-AHA-cAMP (site B-selective).
Pairs of cAMP analogues that are specific for type II are 8-CPT-cAMP
(site B-selective) and N6B-cAMP (site A-selective). The values are the
mean and S.E. (n 5 4) of the differences in the percentage of cells with
apoptotic morphology in the presence of the cAMP analogue versus
control. The effects of each analogue alone are indicated in the column
headed “A or B.” The columns headed “Predicted (A 1 B)” indicate the
values that are predicted for the effects in the presence of two cAMP
analogues if the effects were additive. The column headed “Observed
(A 1 B)” indicates the effects observed when the analogues are incu-
bated together. Type I-specific pairs exhibited synergism indicated by
“Observed (A 1 B)” effects greater than “Predicted (A 1 B)” effects.
Type II-specific pairs exhibited additive effect or the absence of syner-
gism as indicated by “Observed (A 1 B)” effects approximately equal to















25 6.3 6 4
667 8.5 6 5.5 14.3 6 5.9 28.5 6 2.0*
333 0.5 6 1.3 6.8 6 3.3 22.1 6 2.5*
Type II pair
8CPT N6B
25 6.3 6 4
333 38.7 6 3.8 45.0 6 5.8 38.8 6 4.7




75 3.7 6 3.2
1000 14.4 6 2.1 18.1 6 5.0 37.0 6 4.0*
667 9.3 6 2.3 12.9 6 4.5 29.8 6 3.9*
333 7.5 6 3.7 11.2 6 4.9 21.1 6 4.5
Type II pair
8CPT N6B
75 3.7 6 3.2
667 59.9 6 8.0 63.6 6 10.0 50.9 6 7.5
333 24.3 6 3.0 30.0 6 3.9 38.0 6 4.3




100 0.9 6 0.4
1000 0.2 6 0.2 0.7 6 0.4 11.2 6 3.2*
667 3.3 6 2.6 2.9 6 2.9 12.3 6 2*
Type II pair
8CPT N6MB
100 0.9 6 0.4
667 10.2 6 3.7 8.6 6 1.8 10.6 6 2.3
333 15 6 3.8 13.9 6 2.8 14.3 6 3.7

















PD98059. These data indicate that MAPKK is not involved in
CHX-induced apoptosis, that the action of cAPK is independent
of MAPKK, or that cAPK acts downstream of MAPKK activa-
tion. * indicates p . 0.05 by paired t test.
DISCUSSION
Neutrophils are terminally differentiated cells that survive a
limited time in the peripheral blood and tissues. Because of
their central roles in host defense and acute inflammation, the
numbers of cells available and the duration of their survival
are significant to survival of the host. The signals and mecha-
nisms that control production and survival of these cells are
incompletely understood, but both appear to involve apoptosis,
the physiologic form of cellular death that is internally con-
trolled by the cell. We sought to examine the roles of second
messenger, Ca21-based, and cAMP-based signaling in human
neutrophil apoptosis.
Since cAMP was the first second messenger discovered (35)
and is important for regulation of vital functions (e.g. prolifer-
ation, differentiation, gene transcription) in essentially all or-
ganisms, we focused our studies on cAMP and the cAPK in
neutrophils. Cyclic AMP regulates apoptosis in several cell
types, inhibiting or stimulating the process depending on the
cell type and stage of differentiation (17–20). The studies re-
ported here clearly demonstrate that cAMP delays and does not
inhibit apoptosis in a time- and concentration-dependent man-
ner in human neutrophils. Furthermore, activation of cAPK is
required for this effect, as H-89, a potent and selective inhibitor
of cAPK (33), neither induced apoptosis itself nor delayed
apoptosis resulting from in vitro storage, cycloheximide, or
anti-Fas exposure. This suggests that basal levels of cAPK
activity do not play significant roles in neutrophil apoptosis.
Use of site-selective cAMP analogues allowed clear demonstra-
tion that the type I cAPK, but not the type II, mediates the
delay in apoptosis. This is consistent with the observation that
the type I cAPK is the predominant isoform in human neutro-
phils, comprising about 85% of total cAPK. The complete lack of
synergism when type II pairs were used indicates that the type
II cAPK is either unnecessary, not sufficient, or localized (36) in
a compartment that is not exposed to substrates needed for
delaying apoptosis. It could be argued that the levels of type II
cAPK are below the levels of sensitivity for this method. How-
ever, this is unlikely because very low levels of cAMP and cAPK
activation are required for cAPK-mediated events, and syner-
gism is a result of the cooperative activation of cAPK, which
serves as a physiologically relevant means to amplify cAMP
signals.
Other studies have demonstrated that elevation of cAMP by
forskolin prostaglandin E2-mimics, and inhibitors of cAMP
phosphodiesterases inhibits apoptosis in neutrophils (17). It is
possible that elevation of endogenous cAMP levels by agonists
such as adrenergic agents, prostaglandins, or other agents in
tissues may serve to delay apoptosis and prolong the life of
neutrophils in vivo under certain circumstances. Generally,
elevation of cAMP levels is transient, and prolonged elevation
of cAMP is subject to feedback mechanisms that interrupt
cAPK signal in various ways. The studies presented here dem-
onstrate that even in the presence of sustained elevation of
cAMP levels using relatively stable cAMP analogues, apoptosis
is only delayed and not inhibited as reported by others (17).
However, for neutrophils, which have relatively short life
spans, this delay in apoptosis would be expected to be signifi-
cant. Activation of type I cAPK is also associated with attenu-
ation of the respiratory burst,2 suggesting that cAPK prolongs
the life of neutrophils with some attenuated functions. This
may serve to protect the host against neutrophil-mediated
inflammation.
Apoptosis is a complex cellular process that mediates a tran-
sition from life to death in most cell types. The process involves
diverse structural and biochemical changes, three of which we
used as markers in these studies. Many investigators have
used morphologic changes to identify apoptotic cells. For neu-
trophils in single cell suspension, this marker is definitive and
quantitative but is not likely to be an early event in the
apoptosis process. In comparison, annexin V-FITC binding
identifies membrane asymmetry due to transposition of phos-
phatidylserine from the inner to the outer leaflet of the surface
membrane (31). Development of this asymmetry may be an
2 L. K. Parvathenani, E. S. Buescher, E. Chacon-Cruz, and S. J.
Beebe, unpublished data.
FIG. 4. Effect of 8-CPT-cAMP on caspase-3 (CPP32b) activity.
Isolated neutrophils were incubated in the presence or absence of 500
mM 8-CPT-cAMP, and apoptosis was induced by in vitro culture, CHX
exposure, or anti-Fas exposure. At the indicated times, cells were lysed,
and DEVD-AFC specific activity was determined as described under
“Materials and Methods.” A, time course of the effect of 500 mM 8CPT-
cAMP in the presence and absence of CHX on caspase-3 activity as
determined by cleavage of DEVD-AFC was measured at 2, 4, and 6 h
time points. The figure represent the mean 6 S.E. of four different
donors. B, the effect of 500 mM 8CPT-cAMP on caspase-3 activity in
whole cell extracts of cells maintained in vitro for 24 h (n 5 4), exposed
to CHX(1 mM) for 4 h (n 5 4), or anti-Fas (500 ng/ml) for 4 h (n 5 4).

















early marker for apoptosis, which allows selective recognition
and clearance of the apoptotic cell from its normal environ-
ment. In close agreement with apoptotic morphology, annexin
V-FITC binding also clearly defined the cAMP-mediated delay
in apoptosis and was a more sensitive marker for apoptosis and
the effects of cAPK. Chromatin fragmentation was used as a
third, qualitative marker for apoptosis. This fragmentation
results from cleavage of chromatin into approximately 200-
base pair fragments by a Ca21-dependent endonuclease (28).
This marker confirmed that the morphologic and annexin V-
FITC binding changes observed in cycloheximide-exposed cells
were associated with chromatin fragmentation, but because
this marker is not quantitative, it was not used to examine
cAMP effects or apoptosis induced by either in vitro storage of
anti-Fas exposure. Thus, we used two functionally distinct
quantitative markers to demonstrate apoptosis and the effects
on cAMP on apoptosis and found consistency between them.
These studies leave little doubt that cAPK are important reg-
ulators for delaying apoptosis in neutrophils.
Because apoptosis can result from different stimuli, we used
three different models of the process in these studies. The
precise mechanisms underlying storage-induced and cyclohex-
imide-induced apoptosis are not known, although stimulation
of the S6 kinase and signaling via the mitogen-activated pro-
tein kinase pathway may be involved in the CHX model (37,
38). However, anti-Fas exposure has been and continues to be
intensively studied, because apoptosis in this situation results
from receptor activation at the cell surface and now has a
relatively well defined pathway. Cyclic AMP and type I cAPK
delayed apoptosis in each of these diverse models, raising ques-
tions about the mechanisms of action and the site(s) of action
for cAPK in each model. Previous studies suggested that a
delay in apoptosis was accompanied by a transient Ca21 spike
(34). In the results presented here, neither the induction of
apoptosis by CHX nor the delay of apoptosis by cAMP ana-
logues was associated with changes in intracellular Ca21
levels.
We investigated the possibility that by analyzing the well
defined actions of the cAPK pathway and determining the sites
for cAPK action in human neutrophils, the regulatory sites in
one or more pathways for apoptosis could be identified. Cyclic
AMP and cAPK could modulate each of the models used in this
study at different sites, some shared and some unique or could
act at a single site common to all pathways. Several experi-
mental observations suggest that cAPK acts at different sites
in each of the models. Although cAMP inhibition is present in
all models, the sensitivity to cAMP differs across models: cAMP
prolonged neutrophil survival 3.3-, 2.6-, and 1.4-fold in the
cycloheximide exposure, in vitro storage, and anti-Fas exposure
models, respectively. If cAPK acted at a common site in each
model, it might reasonably be expected that inhibition would be
quantitatively similar. However, it is possible that the inten-
sity of the apoptosis signal is different in each model, and
despite a common site of action, cAPK is more effective in some
models than in others. A second observation against a common
point of action for cAPK in all models is that inhibition of
disparate processes (annexin V-FITC binding and morphologic
apoptosis) resulted from cAMP exposure. The possibility that
surface membrane changes and morphologic changes occur as
temporally distinct events also suggests that cAPK has multi-
ple sites of action, as might be expected for a multisubstrate
kinase (39). Nevertheless, it could be argued that each of the
markers used here occur as a result of a common event, such as
caspase-3 (CPP-32b) activation.
Alternatively, it is possible that the same site of cAPK action
is common to all models, with the different pathways initiated
in each model converging to a common path that involves
cAPK. Because cAPK generally acts at rate-limiting steps, it is
likely that the site(s) will be an important regulatory locus for
control of the process. Studies with the caspase substrates
suggest that cAPK acts upstream of caspase-3. It is highly
likely that the activation of caspase-3 may be a point of no
return in the apoptosis pathway (10). Although sites down-
stream of caspase-3 activation may modulate apoptosis, it is
expected that they are less effective than sites upstream of
protease activation. Cyclic AMP/cAPK action upstream of a
putative committed step for apoptosis is consistent with cAPK
action at a rate-dependent or process-dependent point in apo-
ptosis pathways.
Activation of the mitogen-activated protein kinase pathway
has been shown to delay apoptosis in a number of cell types
(40). We thus used PD98059 to block the activation of MAPKK
before the addition of CHX or cAMP and observed the effects of
these agents on apoptotic morphology. PD98059 has been
shown to readily cross the cell membrane and to be a highly
selective inhibitor of MAPKK1 (24). PD98059 had no effect on
the cAPK-mediated delay in apoptosis in the CHX model. This
suggests that MAPKK activation is not involved in this model
of apoptosis, or if it is involved, cAPK may be acting at a site(s)
downstream of or independent of MAPKK to delay CHX-in-
duced apoptosis. Taken together, these results suggests that
cAPK acts at a relatively downstream site but upstream of a
critical determinant of apoptosis that may be common to all
apoptosis pathways.
In summary, our data demonstrate for the first time that
through activation of type I cAPK, cAMP delays, but does not
prevent, apoptosis in human neutrophils due to in vitro stor-
age, cycloheximide exposure, and anti-Fas exposure. A quanti-
tative and temporal analysis of apoptosis in the presence and
absence of cAMP analogues using different models, distinct
markers, kinase inhibitors, and caspase substrates suggest
that the type I cAPK acts at multiple sites that could be either
unique or common to the models used in this study. However,
a major site of cAPK action is before caspase activation, which
may be a common and committed step in all models of apoptosis
(10). Cyclic AMP and cAPK may represent a potential thera-
peutic target for prolonging the life span of myeloid cells in vivo
and in vitro.
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